Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

volanesorsen

- PMLiVE

AstraZeneca/Ionis’ Wainzua receives positive CHMP opinion to treat rare disease ATTRv-PN

The drug can be self-administered via an auto-injector and is designed to lower the production of TTR protein at its source

- PMLiVE

AstraZeneca and Ionis’ Wainua granted FDA approval for rare disease ATTRv-PN

ATTRv-PN leads to peripheral nerve damage with motor disability within five years of diagnosis

- PMLiVE

Biogen pays Ionis $60m for licence to develop ASO for spinal muscular atrophy

The licence is worldwide and exclusive and may include future royalty payments

- PMLiVE

Biogen bets on Ionis’ early-stage Alzheimer’s drug

Paid $45m upfront with potential milestones of up to $155m

- PMLiVE

GSK to develop Ionis hepatitis B drugs

Competing with rivals Gilead to find cure for 200 million people

- PMLiVE

Akcea steals march on Alnylam with NICE approval

Advantage to Tegsedi over Onpattro

- PMLiVE

Novartis in-licenses Akcea’s novel cardiovascular therapy

Lp(a) targeting therapy could treat millions

- PMLiVE

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

Room for manoeuvre after initial rejection

- PMLiVE

Biogen picks up another drug from wide-ranging Ionis alliance

Aims to follow success of Spinraza

- PMLiVE

Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

FDA rejects Waylivra, Roivant group continues gene therapy drive, UK biotech gains £637k

- PMLiVE

Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

More good news for Ionis after first drug approval

- PMLiVE

Despite FDA concerns, Akcea rare disease drug clears FDA panel

FDA now set to deliver final verdict by 30 August

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links